Anti-Factor VII, Recombinant [RFF-VII/1]
Invented at University College London
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153357 |
| Applications | ELISA Fn WB |
| Antigen/Gene or Protein Targets | Factor VII |
| Reactivity | Human |
| Relevance | Factor VII is a 50kDa multi-domain, single chain plasma glycoprotein synthesised in the liver. It is essential for blood coagulation. Factor VII is converted to the active, two chain, serine protease Factor VIIa via cleavage by thrombin, factor Xa, factor IXa or factor XIIa. Factor VIIa converts factor X to factor Xa, which in turn converts prothrombin to thrombin. This monoclonal antibody partially inhibits human Factor VII activity. |
| Host | Mouse |
| Immunogen | Purified human factor VII |
| Subclass | IgG1 kappa |
| Formulation | PBS |
| Concentration | 1mg/ml |
| Research Area | Cardiovascular |
| Notes | Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. |
References: 1 entry
Original hybridoma first published in: Takase et al. 1988. J Clin Pathol. 41(3):337-41. PMID: 3360957.
Add a reference
References: 1 entry
Original hybridoma first published in: Takase et al. 1988. J Clin Pathol. 41(3):337-41. PMID: 3360957.
Add a reference
